SCHEMBL8962425

SCHEMBL8962425

CC(C)c1cccc(C(C)C)c1NS(=O)(=O)CC(=O)Sc1c(C(C)C)cccc1C(C)C

nearest known ligand 0.51

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8962463 0.91 MAPK1 (0.41) SMN1; SMN2
SCHEMBL8962380 0.81 LMNA (0.47) SMN1; SMN2
SCHEMBL8962531 0.81 SMN1; SMN2 (0.47) SMN1; SMN2
SCHEMBL9390816 0.80 SMN1; SMN2 (0.50) SMN1; SMN2
SCHEMBL8962535 0.78 SMN1; SMN2 (0.60) SMN1; SMN2
SCHEMBL8962527 0.78
SCHEMBL8962505 0.78
SCHEMBL8962355 0.78
SCHEMBL8962555 0.78
SCHEMBL8962767 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5491170-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-02-13 US claimed
WO-1996019446-A1 β-CARBOXY SULFONAMIDE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1996-06-27 WO disclosed
US-5491170-A TREATMENT OF HYPERCHOLESTEROLEMIA AND ATHEROSCLEROSIS WARNER-LAMBERT COMPANY (US) 1996-02-13 US disclosed